Home › Multiple Myeloma › California › Los Angeles
Pag-aaral pangklinika para sa Multiple Myeloma sa Los Angeles, CA
Isang pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Los Angeles. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Valkyrie Clinical Trials, Los Angeles
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Nagre-recruitPhase 4
- Berenson Cancer Center, Los Angeles
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Nagre-recruitPhase 3
- Valkyrie Clinical Trials, Los Angeles
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Nagre-recruitPhase 2
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Nagre-recruitPhase 2/3
- Cedars-Sinai Medical Center /ID# 278238, Los Angeles
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Nagre-recruitPhase 3
- UCLA Hematology/Oncology - Santa Monica, Los Angeles
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214), Los Angeles
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Nagre-recruitPhase 1/2
- University of Southern California /ID# 272414, Los Angeles
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Nagre-recruitPhase 3
- Clinical Research Advisors (Korea Town Satellite Location), Los Angeles
- Clinical Research Advisors (West Hollywood Satellite Location), Los Angeles
- Valkyrie Clinical Trials, Los Angeles
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Nagre-recruitPhase 1/2
- GSK Investigational Site, Los Angeles
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Los Angeles
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Nagre-recruitPhase 1
- Cedars-Sinai Medical Center, Los Angeles
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
Nagre-recruit
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars Sinai Medical Center, Los Angeles
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Nagre-recruitPhase 3
- UCLA Medical Center, Los Angeles
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Nagre-recruitPhase 1/2
- University of California Los Angeles (UCLA), Los Angeles
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Nagre-recruitPhase 1/2
- Valkyrie Clinical Trials, Los Angeles
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO27 pag-aaral
- St. Louis, MO24 pag-aaral
- Rochester, MN24 pag-aaral
- Columbus, OH24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- Edison, NJ22 pag-aaral
Iba pang pag-aaral sa Los Angeles
- Non-Small Cell Lung Cancer87 pag-aaral
- Kanser (lahat ng uri)74 pag-aaral
- Kanser sa Suso73 pag-aaral
- Kanser sa Prostate61 pag-aaral
- Colorectal Cancer59 pag-aaral
- Metastatic Cancer57 pag-aaral
- Kanser sa Ovary50 pag-aaral
- Kanser sa Baga45 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg42 pag-aaral
- Kanser sa Pancreas35 pag-aaral
- Kanser ng Endometrium34 pag-aaral
- Melanoma34 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.